ATE80660T1 - Verfahren zur herstellung eines polypeptides. - Google Patents

Verfahren zur herstellung eines polypeptides.

Info

Publication number
ATE80660T1
ATE80660T1 AT87902674T AT87902674T ATE80660T1 AT E80660 T1 ATE80660 T1 AT E80660T1 AT 87902674 T AT87902674 T AT 87902674T AT 87902674 T AT87902674 T AT 87902674T AT E80660 T1 ATE80660 T1 AT E80660T1
Authority
AT
Austria
Prior art keywords
pct
polypeptide
secretion sequence
production
terminal secretion
Prior art date
Application number
AT87902674T
Other languages
English (en)
Inventor
Ian Barry Holland
Nigel Mackman
Jean-Marc Nicaud
Original Assignee
Ian Barry Holland
Nigel Mackman
Nicaud Jean Marc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ian Barry Holland, Nigel Mackman, Nicaud Jean Marc filed Critical Ian Barry Holland
Application granted granted Critical
Publication of ATE80660T1 publication Critical patent/ATE80660T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6478—Aspartic endopeptidases (3.4.23)
    • C12N9/6481—Pepsins (3.4.23.1; 3.4.23.2; 3.4.23.3)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT87902674T 1986-05-15 1987-05-14 Verfahren zur herstellung eines polypeptides. ATE80660T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB868611832A GB8611832D0 (en) 1986-05-15 1986-05-15 Polypeptide
PCT/GB1987/000331 WO1987006953A1 (en) 1986-05-15 1987-05-14 Process for the production of a polypeptide
EP87902674A EP0267224B1 (de) 1986-05-15 1987-05-14 Verfahren zur herstellung eines polypeptides

Publications (1)

Publication Number Publication Date
ATE80660T1 true ATE80660T1 (de) 1992-10-15

Family

ID=10597902

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87902674T ATE80660T1 (de) 1986-05-15 1987-05-14 Verfahren zur herstellung eines polypeptides.

Country Status (9)

Country Link
US (1) US5143830A (de)
EP (1) EP0267224B1 (de)
JP (1) JPS63503274A (de)
AT (1) ATE80660T1 (de)
AU (1) AU600949B2 (de)
DE (1) DE3781765T2 (de)
DK (1) DK13788A (de)
GB (2) GB8611832D0 (de)
WO (1) WO1987006953A1 (de)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
US5037743A (en) * 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US6210948B1 (en) 1992-06-09 2001-04-03 The University Of British Columbia Expression and secretion of heterologous polypeptides from caulobacter
US5914254A (en) * 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
US5563046A (en) * 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
US6214794B1 (en) 1994-12-02 2001-04-10 The Johns Hopkins University School Of Medicine Method of using hedgehog polypeptides to regulate neuronal cell growth
US6281332B1 (en) * 1994-12-02 2001-08-28 The Johns Hopkins University School Of Medicine Hedgehog-derived polypeptides
US6911528B1 (en) 1994-12-02 2005-06-28 The Johns Hopkins University School Of Medicine Hedgehog-derived polypeptides
US6057091A (en) * 1994-12-02 2000-05-02 The Johns Hopkins University School Of Medicine Method of identifying compounds affecting hedgehog cholesterol transfer
US6770275B1 (en) * 1996-05-31 2004-08-03 Akzo Nobel N.V. Live attenuated RTC-producing bacteria of the family
IL129379A (en) 1996-10-16 2008-12-29 Zymogenetics Inc Fibroblast growth factor homologues
US6036953A (en) * 1996-11-29 2000-03-14 The General Hospital Corporation Heterologous antigens in live cell V. cholerae strains
CA2284733C (en) 1997-03-24 2010-10-26 Zymogenetics, Inc. Motilin homologs
MXPA00012241A (es) 1998-06-10 2002-06-04 Novozymes As Mananasas novedosas.
EP1115862B1 (de) 1998-09-23 2009-07-15 ZymoGenetics, Inc. Cytokinerezeptor zalpha11
AU764039B2 (en) 1998-12-07 2003-08-07 Zymogenetics Inc. Growth factor homolog ZVEGF3
SK288176B6 (sk) 1999-01-07 2014-04-02 Zymogenetics, Inc. Farmaceutický prostriedok obsahujúci fúzny proteín, izolovaná molekula polynukleotidu, expresný vektor, kultivovaná bunka, spôsob prípravy polypeptidu a izolovaný polypeptid
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
CA2261186A1 (en) 1999-02-19 2000-08-19 University Of British Columbia Expression and secretion of heterologous polypeptides from freshwater caulobacter
ATE377076T1 (de) 1999-03-09 2007-11-15 Zymogenetics Inc Humanes cytokin als ligand des zalpha rezeptors und dessen verwendungen
US6664386B1 (en) 1999-04-08 2003-12-16 The Research Foundation Of State University Of New York System for efficient secretion of recombinant proteins
ES2286029T3 (es) 1999-07-07 2007-12-01 Zymogenetics Inc Receptor de citocina humano.
AU2136601A (en) * 1999-12-17 2001-06-25 University Of Guelph Modified leukotoxin gene and protein
WO2001046422A1 (en) 1999-12-23 2001-06-28 Zymogenetics, Inc. Novel cytokine zcyto18
WO2001077171A2 (en) 2000-04-05 2001-10-18 Zymogenetics, Inc. Soluble zalpha11 cytokine receptors
DK1325115T3 (en) 2000-06-26 2016-11-21 Zymogenetics Inc CYTOKINRECEPTOR ZCYTOR17
US7795002B2 (en) * 2000-06-28 2010-09-14 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
US7863020B2 (en) 2000-06-28 2011-01-04 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
CN100448993C (zh) 2000-06-30 2009-01-07 津莫吉尼蒂克斯公司 干扰素样蛋白质Zcyto21
EP1736545A3 (de) 2000-08-08 2007-03-28 ZymoGenetics, Inc. Lösliche Zcyctor 11 Cytokinrezeptoren
KR100447530B1 (ko) * 2001-08-14 2004-09-08 한국과학기술원 ＯｍｐＦ를 이용하여 목적 단백질을 대장균 세포외로분비생산하는 방법
CA2463631C (en) 2001-10-15 2012-07-03 Engeneic Gene Therapy Pty Limited Intact minicells as vectors for dna transfer and gene therapy in vitro and in vivo
ES2334338T3 (es) 2001-11-05 2010-03-09 Zymogenetics, Inc. Antagonistas de il-21.
AU2002359721A1 (en) * 2001-12-19 2003-07-09 Bristol-Myers Squibb Company Pichia pastoris formate dehydrogenase and uses therefor
ATE401390T1 (de) 2002-01-18 2008-08-15 Zymogenetics Inc Zytokin (zcytor17-ligand)
EP1576112B1 (de) 2002-01-18 2012-02-29 ZymoGenetics, Inc. Multimere des cytokinrezeptors zcytor17
CN1659274A (zh) 2002-04-19 2005-08-24 津莫吉尼蒂克斯公司 细胞因子受体
CA2487133A1 (en) 2002-06-07 2003-12-18 Zymogenetics, Inc. Use of il-21 in cancer and other therapeutic applications
DE602004029868D1 (de) * 2003-03-05 2010-12-16 Chemo Sero Therapeut Res Inst Verfahren zur herstellung eines heterologen proteins in e. coli
US20040241677A1 (en) * 2003-05-29 2004-12-02 Lin Jeffrey S Techniques for automated diagnosis of cell-borne anomalies with digital optical microscope
ES2296423B1 (es) * 2003-07-31 2009-03-16 Consejo Sup. Investig. Cientificas Construccion de adn para la produccion de proteinas de fusion dimericas y sus aplicaciones.
ES2303132T3 (es) 2003-08-07 2008-08-01 Zymogenetics, Inc. Preparaciones homogeneas de il-29.
EP1653995A1 (de) 2003-08-08 2006-05-10 Novo Nordisk A/S Interleukin-20 zur behandlung und diagnose von mit neovaskularization verbunden zuständen
EP1673387B1 (de) 2003-10-10 2010-09-15 Novo Nordisk A/S Il-21-derivate
ES2428358T3 (es) 2003-10-17 2013-11-07 Novo Nordisk A/S Terapia de combinación
EP1694361B1 (de) 2003-12-09 2011-03-16 EnGeneIC Molecular Delivery Pty Ltd. Gezielte genabgabe an nicht-phagozytische säugetierzellen über bakteriell erhaltene intakte minizellen
US7381794B2 (en) 2004-03-08 2008-06-03 Zymogenetics, Inc. Dimeric fusion proteins and materials and methods for producing them
CA2574564C (en) 2004-07-29 2013-04-16 Zymogenetics, Inc. Use of il-28 and il-29 to treat cancer and autoimmune disorders
AU2005268917B2 (en) 2004-08-02 2010-05-20 Basf Plant Science Gmbh Method for isolation of transcription termination sequences
DK2386640T3 (en) 2004-08-26 2015-04-27 Engeneic Molecular Delivery Pty Ltd The making of functional nucleic acids into mammalian cells via bacterially derived intact minicells
WO2006086396A2 (en) 2005-02-08 2006-08-17 Zymogenetics, Inc. Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
ES2609429T3 (es) 2005-05-12 2017-04-20 Zymogenetics, Inc. Composiciones y métodos para modular respuestas inmunitarias
US7393667B2 (en) * 2005-05-31 2008-07-01 Bristol-Myers Squibb Company Stereoselective reduction process for the preparation of pyrrolotriazine compounds
WO2007019573A2 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
AU2006278229B2 (en) * 2005-08-09 2011-10-27 Ares Trading S.A. Methods for treating B-cell malignancies using TACI-Ig fusion molecule
KR20090016707A (ko) * 2006-05-15 2009-02-17 아레스 트레이딩 에스.에이. Ｔａｃｉ­ｉｇ 융합 분자를 사용하여 자가면역 질병을 치료하는 방법
PL2712618T3 (pl) 2006-06-23 2017-07-31 Engeneic Molecular Delivery Pty Ltd. Ukierunkowane dostarczanie leków, terapeutycznych kwasów nukleinowych i funkcjonalnych kwasów nukleinowych do komórek ssaczych przez nienaruszone, uśmiercone komórki bakteryjne
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US8318664B2 (en) 2007-05-31 2012-11-27 Alize Pharma Sas Unacylated ghrelin fragments as therapeutic agent in the treatment of obesity
ES2538111T3 (es) * 2007-05-31 2015-06-17 Alizé Pharma SAS Grelina no acilada como agente terapéutico en el tratamiento de trastornos metabólicos
JP5496897B2 (ja) 2007-10-04 2014-05-21 ザイモジェネティクス， インコーポレイテッド Ｂ７ファミリーメンバーのｚＢ７Ｈ６ならびに関連する組成物および方法
KR101700711B1 (ko) 2007-11-21 2017-01-31 로스킬드 유니베르시테트 얼음-결합 활성을 포함하는 폴리펩티드
WO2009080054A1 (en) * 2007-12-21 2009-07-02 Ifxa A/S Protease inhibitor
JP5727792B2 (ja) * 2008-01-25 2015-06-03 オーフス ユニバーシテ Ｉｇｆｂｐ−４に対するｐａｐｐ−ａ活性の選択的エキソサイト阻害
SI2274008T1 (sl) 2008-03-27 2014-08-29 Zymogenetics, Inc. Sestavki in metode za zaviranje PDGFRBETA in VEGF-A
CN102131517B (zh) 2008-06-27 2014-12-17 津莫吉尼蒂克斯公司 可溶性杂合Fc γ受体和相关的方法
CA2733425A1 (en) 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccines against clostridium difficile and methods of use
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
MX2012013899A (es) 2010-06-09 2013-03-20 Zymogenetics Inc Proteinas de fusion vstm3 dimericas y composiciones y metodos relacionados.
EP2670426B1 (de) 2011-01-31 2017-05-10 The General Hospital Corporation Multimodale trail-moleküle und ihre verwendungen in zelltherapien
EP2583975A1 (de) * 2011-10-21 2013-04-24 Heinrich-Heine-Universität Düsseldorf Mittel und Verfahren zur Expression und Sekretion von Peptiden und Proteinen
EP2809795B1 (de) 2012-02-01 2019-09-18 SGI-DNA, Inc. Materialien und verfahren zur synthese von fehlerminimierten nucleinsäuremolekülen
WO2014018113A1 (en) 2012-07-24 2014-01-30 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
US9605074B2 (en) 2012-08-30 2017-03-28 The General Hospital Corporation Multifunctional nanobodies for treating cancer
AU2013312838B2 (en) 2012-09-04 2018-11-29 Cellectis Multi-chain chimeric antigen receptor and uses thereof
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
JP6465794B2 (ja) * 2013-04-25 2019-02-06 株式会社カネカ Ｆａｂ型抗体の分泌量を増大できるＦｄ鎖遺伝子又はＬ鎖遺伝子
PL2997141T3 (pl) 2013-05-13 2023-02-06 Cellectis Chimeryczny receptor antygenowy swoisty względem cd19 i jego zastosowania
WO2014202089A2 (en) 2013-06-18 2014-12-24 Roskilde Universitet Variants of anti-freeze polypeptides
US20160303174A1 (en) 2013-12-11 2016-10-20 The General Hospital Corporation Stem cell delivered oncolytic herpes simplex virus and methods for treating brain tumors
EP3808410A1 (de) 2013-12-20 2021-04-21 Cellectis Verfahren zur manipulation von für mehrere eingangssignale empfindlichen t-zellen zur immuntherapie
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
CA2943008C (en) 2014-03-19 2021-03-30 Cellectis Cd123 specific chimeric antigen receptors for cancer immunotherapy
EP3137498A1 (de) 2014-05-02 2017-03-08 Cellectis Cs1-spezifischer mehrkettiger chimärer antigenrezeptor
KR102048855B1 (ko) 2014-07-29 2019-11-26 셀렉티스 암 면역요법을 위한 ror1(ntrkr1) 특이적 키메라 항원 수용체
CA2956482A1 (en) 2014-07-31 2016-02-04 Cellectis Ror1 specific multi-chain chimeric antigen receptor
EP3699188A1 (de) 2014-09-04 2020-08-26 Cellectis 5t4(tpbg)-spezifische chimäre antigenrezeptoren für die krebsimmuntherapie
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US20180002435A1 (en) 2015-01-26 2018-01-04 Cellectis mAb-DRIVEN CHIMERIC ANTIGEN RECEPTOR SYSTEMS FOR SORTING/DEPLETING ENGINEERED IMMUNE CELLS
JP6921001B2 (ja) 2015-04-13 2021-08-18 ファイザー・インク Ｂ細胞成熟抗原を標的にするキメラ抗原受容体
US20180112006A1 (en) 2015-04-17 2018-04-26 The General Hospital Corporation Agents, systems and methods for treating cancer
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2016185035A1 (en) 2015-05-20 2016-11-24 Cellectis Anti-gd3 specific chimeric antigen receptors for cancer immunotherapy
JP6953020B2 (ja) 2015-09-08 2021-10-27 セリピオン， インコーポレイテッド ＡｐｏＡ−１融合ポリペプチドならびに関連する組成物および方法
MX2018003292A (es) 2015-09-21 2018-08-01 Aptevo Res & Development Llc Polipéptidos de unión a cd3.
EA201891641A1 (ru) 2016-01-21 2019-01-31 Пфайзер Инк. Химерные антигенные рецепторы, нацеленные на вариант iii рецептора эпидермального фактора роста
US11485976B2 (en) 2016-10-06 2022-11-01 Engeneic Molecular Delivery Pty Ltd Bacterial minicells for delivering nucleic acid adjuvants and methods of using the same
WO2018073394A1 (en) 2016-10-19 2018-04-26 Cellectis Cell death inducing chimeric antigen receptors
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2018136163A2 (en) 2016-12-09 2018-07-26 Theripion, Inc. Tandem apoa-1 fusion polypeptides
ES2979232T3 (es) 2017-03-31 2024-09-25 Cellectis Sa Células inmunitarias con receptor de antígeno quimérico anti-CD22 universal
US20200399343A1 (en) 2017-04-19 2020-12-24 Allogene Therapeutics, Inc. Improved t cell compositions and methods
US12296012B2 (en) 2017-06-02 2025-05-13 Pfizer Inc. Chimeric antigen receptors targeting FLT3
CA3067914A1 (en) 2017-06-30 2019-01-03 Cellectis Cellular immunotherapy for repetitive administration
CA3070272A1 (en) 2017-07-20 2019-01-24 Aptevo Research And Development Llc Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
WO2019072824A1 (en) 2017-10-09 2019-04-18 Cellectis IMPROVED ANTI-CD123 CAR IN UNIVERSAL MODIFIED IMMUNE T LYMPHOCYTES
US11326156B2 (en) 2017-11-01 2022-05-10 Allogene Therapeutics, Inc. Modified caspase-9 polypeptides and methods of use thereof
DK3710484T5 (da) 2017-12-20 2024-08-26 Harbour Biomed Shanghai Co Ltd Ctla-4-bindende antistoffer og anvendelser deraf
ES3039238T3 (en) 2017-12-27 2025-10-20 Imunami Laboratories Pte Ltd Recombinant polypeptides and methods of use thereof
US10150801B1 (en) 2017-12-27 2018-12-11 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and methods of use thereof
PE20210708A1 (es) 2018-02-01 2021-04-16 Pfizer Anticuerpos especificos para cd70 y sus usos
IL276396B2 (en) 2018-02-01 2026-01-01 Pfizer Chimeric antigen receptors against CD70
EP3759132A1 (de) 2018-03-02 2021-01-06 Allogene Therapeutics, Inc. Induzierbare chimäre zytokinrezeptoren
EP3817767A1 (de) 2018-07-02 2021-05-12 Cellectis Chimäre antigen-rezeptoren (auto) exprimierende zellen und kombinationstherapie zur immuntherapie von patienten mit rezidivierender oder refraktärer aml mit genetischem risiko
WO2020099572A1 (en) 2018-11-14 2020-05-22 Fundación Pública Andaluza Progreso Y Salud Polynucleotide for safer and more effective immunotherapies
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
AU2020329217A1 (en) 2019-08-12 2022-07-28 Aptevo Research And Development Llc 4-1BB and OX40 binding proteins and related compositions and methods, antibodies against 4-1BB, antibodies against OX40
WO2021040610A1 (en) 2019-08-26 2021-03-04 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and methods of use thereof
US10675332B1 (en) 2019-08-26 2020-06-09 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and methods of use thereof
US12285437B2 (en) 2019-10-30 2025-04-29 The Research Foundation For The State University Of New York Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity
CA3172201A1 (en) 2020-03-18 2021-09-23 Arthur Tinkelenberg Anti-ceramide antibodies
EP3882260A1 (de) * 2020-03-18 2021-09-22 NUMAFERM GmbH Fragmente von hlya und verwendungen davon
WO2021185969A1 (en) 2020-03-18 2021-09-23 Numaferm Gmbh Variants of hlya and uses thereof
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CA3182917A1 (en) 2020-06-22 2021-12-30 Ya-Huei Chen Recombinant polypeptides and combinations for use in the treatment of cancer
CN116194488A (zh) 2020-07-21 2023-05-30 艾洛基治疗公司 具有增强的信号传导和活性的嵌合抗原受体和其用途
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
JP2023541705A (ja) 2020-09-21 2023-10-03 フンダシオン プブリカ アンダルーサ プログレソ イ サルー Ｔ細胞における生理学的発現のためのポリヌクレオチド
US20240301086A1 (en) 2020-12-01 2024-09-12 Aptevo Research And Development Llc Tumor-associated antigens and cd3-binding proteins, related compositions, and methods
WO2022140388A1 (en) 2020-12-21 2022-06-30 Allogene Therapeutics, Inc. Protease-activating cd45-gate car
EP4284918A1 (de) 2021-01-29 2023-12-06 Allogene Therapeutics, Inc. Knockdown oder knockout von einem oder mehreren von tap2, nlrc5, beta2m, trac, rfx5, rfxap und rfxank zur verringerung der t-zellerkennung allogener zellprodukte
CA3207134A1 (en) 2021-02-19 2022-08-25 Jeffrey A. Ledbetter Dnase fusion polypeptides and related compositions and methods
KR20230151518A (ko) 2021-03-04 2023-11-01 알로젠 테라퓨틱스 인코포레이티드 치료 세포를 동종이계 거부반응 및 활성화 유도된 세포 사멸로부터 보호하기 위한 FasL 발현 및 FasR 유전자 녹아웃
US20240228553A1 (en) 2021-03-18 2024-07-11 Numaferm Gmbh Fusion proteins comprising gg repeat sequences
MX2023014866A (es) 2021-06-15 2024-01-16 Allogene Therapeutics Inc Direccionamiento selectivo de celulas alorreactivas cd70+ huesped para prolongar la persistencia de las celulas t con car alogenicas.
WO2023192895A1 (en) 2022-03-29 2023-10-05 Allogene Therapeutics Inc. Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals
CN119654406A (zh) 2022-07-29 2025-03-18 艾洛基治疗公司 具有降低的基因表达以减轻免疫细胞识别的经工程化的细胞
EP4339202A1 (de) 2022-09-16 2024-03-20 NUMAFERM GmbH Fusionsproteine mit gg-wiederholungssequenzen ii
JP2026501724A (ja) 2023-01-06 2026-01-16 アプティーボ リサーチ アンド デベロップメント エルエルシー 二重特異性ｐｄ－ｌ１及びｃｄ４０結合分子ならびにその使用
WO2024259220A1 (en) 2023-06-15 2024-12-19 Theripion, Inc. Pon3 and evolved pon1 fusion polypeptides
WO2025096560A1 (en) 2023-10-30 2025-05-08 Allogene Therapeutics, Inc. Engineered cells

Also Published As

Publication number Publication date
GB8611832D0 (en) 1986-06-25
WO1987006953A1 (en) 1987-11-19
DK13788D0 (da) 1988-01-13
DE3781765T2 (de) 1993-04-22
EP0267224A1 (de) 1988-05-18
JPS63503274A (ja) 1988-12-02
AU600949B2 (en) 1990-08-30
DK13788A (da) 1988-03-15
DE3781765D1 (de) 1992-10-22
AU7392387A (en) 1987-12-01
GB8800141D0 (en) 1988-03-02
GB2197324B (en) 1990-04-11
EP0267224B1 (de) 1992-09-16
GB2197324A (de) 1988-05-18
US5143830A (en) 1992-09-01

Similar Documents

Publication Publication Date Title
ATE80660T1 (de) Verfahren zur herstellung eines polypeptides.
ATE46536T1 (de) Verfahren zur herstellung von reifen proteinen in wirtzellen von wirbeltieren.
ATE121781T1 (de) Verwendung von dns-fragmenten, die ein signalpeptid kodieren zur sekretion von reifen proteinen in rekombinanten hefen, expressions- kassetten, transformierte hefen und verfahren zur herstellung dieser proteine.
ATE160587T1 (de) Expression rekombinanter polypeptide mit verbesserter möglichkeit zur reinigung
DE3587422D1 (de) Fuer ein hirudinaehnliches protein kodierende dns-sequenz und verfahren zur herstellung eines solchen proteins.
IL98024A0 (en) Cd44-surface proteins,dna-sequences coding therefor,polypeptides coded by said dna sequences and diagnostic compositions containing the same
NZ222856A (en) Equine interferon gamma (eq ifn alpha), dna sequences for its recombinant production and monoclonal antibodies thereto
DE69939330D1 (de) Wachstumsfaktor-homologe zvegf-3
DE3881023D1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
ATE71110T1 (de) Verfahren zur reinigung eines proteins.
ATE154362T1 (de) Verfahren zur herstellung von pai-2
ATE253639T1 (de) Verfahren zur herstellung von peptiden
DE3877035D1 (de) Gentechnologisches verfahren zur herstellung von polypeptiden.
ATE169333T1 (de) Verfahren zur herstellung rekombinanter polypeptide mit schweine-wachstumshormonaktivität
MXPA01011158A (es) Factor de crecimiento homologo zvegf4.
DE3873273D1 (de) Verfahren zur selektiven spaltung von fusionsproteinen.
BR1100940A (pt) Polipeptìdeos puros, sequências adn, molécula adn recombinada, célula hospedeira, processo de manipulação genética para produção de polipeptìdeo, e, uso de um polipeptìdeo
DE58909692D1 (de) Verfahren zur selektiven Spaltung von Fusionsproteinen
ATE91303T1 (de) Verfahren zur herstellung von peptiden durch spezifische spaltung von gentechnisch gewonnenen fusionsproteinen mit collagenasen.
ATE83799T1 (de) Verfahren und produkte zur leichten mikrobiologischen expression von dns-sequenzen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee